SAB Biotherapeutics Insider Conversion Adds 1.74M Common Shares
Rhea-AI Filing Summary
SAB Biotherapeutics insider conversion increases public float via Sessa Capital. The filing reports that Series B Convertible Preferred Stock held by Sessa Capital (Master), L.P. automatically converted into 1,740,000 common shares at an effective conversion price of $1.75 per underlying share, reflecting conversion of 17,400 preferred shares. After the conversion the Sessa Parties are reported to beneficially own 2,198,457 common shares in aggregate, held indirectly through related entities.
The Preferred Stock was purchased by the Fund for an aggregate price of $39,987,500 under a July 21, 2025 purchase agreement. The filing discloses a 4.99% beneficial ownership cap that limits further conversions that would push the Sessa Parties above that threshold. Andrew Moin is identified as a board director of the issuer and is an Analyst and Partner with the Fund; the reported holdings are described as indirect and subject to the stated ownership limitation.
Positive
- Automatic conversion completed, converting 17,400 preferred shares into 1,740,000 common shares, clarifying capital structure.
- Purchase price disclosure provided: the Fund acquired the Preferred Stock for an aggregate of $39,987,500, offering transparency on prior investment terms.
- Beneficial ownership clearly mapped through Sessa entities, and the filing discloses Andrew Moin's board role, improving governance transparency.
Negative
- Beneficial ownership cap of 4.99% restricts further conversions that would increase the Sessa Parties' stake beyond that threshold.
- Holdings reported as indirect, which may limit clarity about direct control or voting influence at the individual level.
Insights
TL;DR: Large preferred-to-common conversion adds 1.74M shares to Sessa Parties' stake but is capped at a 4.99% ownership limit.
The conversion increases the issuer's outstanding common shares held by the Sessa Parties by 1,740,000 shares, reflecting automatic conversion mechanics rather than a market purchase. The underlying implied conversion price is $1.75 per share and the Fund's original preferred purchase aggregated $39,987,500. For investors this is a non-cash share increase from conversion, not an open-market trade, and it may modestly increase free float while leaving the Sessa Parties' maximum economic stake constrained by the disclosed 4.99% cap.
TL;DR: Conversion is routine under contract terms; disclosure clarifies indirect ownership and a pre-existing ownership cap.
The Form 4 clearly maps beneficial ownership through the Fund and related entities and names Andrew Moin as a director affiliated with the Fund. The filing emphasizes that the securities are held indirectly by the Fund and related Sessa entities and that each party disclaims ownership beyond pecuniary interest. The 4.99% conversion limit is a material governance mechanism that restricts control amplification through conversion, preserving existing shareholder thresholds and signaling negotiated protective terms in the purchase agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Series B Convertible Preferred Stock | 17,400 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,740,000 | $1.75 | $3.04M |
Footnotes (3)
- F1. Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), of SAB Biotherapeutics, Inc. (the "Issuer"), held by Sessa Capital (Master), L.P. (the "Fund") into common stock, par value $0.0001 per share (the "Common Stock") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock.
- F2. These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the "Sessa Parties"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.
- F3. The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
